Momelotinib treatment-emergent neuropathy: Prevalence, risk factors and outcome in 100 patients with myelofibrosis

Ramy A. Abdelrahman; Kebede H. Begna; Aref Al-Kali; William J.s. Hogan; Mark R. Litzow; Animesh Pardanani; Ayalew Tefferi

doi:10.1111/bjh.13262

Momelotinib treatment-emergent neuropathy: Prevalence, risk factors and outcome in 100 patients with myelofibrosis

Ramy A. Abdelrahman, Kebede H. Begna, Aref Al-Kali, William J.s. Hogan, Mark R. Litzow, Animesh Pardanani, Ayalew Tefferi

Hematology

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment-emergent peripheral neuropathy (TE-PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE-PN onset was 32 weeks and duration 11 months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE-PN was significantly associated with treatment response (P = 0·02) and longer survival (P = 0·048) but significance was lost during multivariate analysis that included treatment duration. TE-PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide.

Original language	English (US)
Pages (from-to)	77-80
Number of pages	4
Journal	British journal of haematology
Volume	169
Issue number	1
DOIs	https://doi.org/10.1111/bjh.13262
State	Published - Apr 1 2015

Keywords

Momelotinib
Myelofibrosis
Myeloproliferative
Neuropathy

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.13262

Cite this

@article{f933c5564fe64a0c8f1cf9e009ad3338,

title = "Momelotinib treatment-emergent neuropathy: Prevalence, risk factors and outcome in 100 patients with myelofibrosis",

abstract = "Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment-emergent peripheral neuropathy (TE-PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE-PN onset was 32 weeks and duration 11 months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE-PN was significantly associated with treatment response (P = 0·02) and longer survival (P = 0·048) but significance was lost during multivariate analysis that included treatment duration. TE-PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide.",

keywords = "Momelotinib, Myelofibrosis, Myeloproliferative, Neuropathy",

author = "Abdelrahman, {Ramy A.} and Begna, {Kebede H.} and Aref Al-Kali and Hogan, {William J.s.} and Litzow, {Mark R.} and Animesh Pardanani and Ayalew Tefferi",

note = "Publisher Copyright: {\textcopyright} 2014 John Wiley & Sons Ltd.",

year = "2015",

month = apr,

day = "1",

doi = "10.1111/bjh.13262",

language = "English (US)",

volume = "169",

pages = "77--80",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Momelotinib treatment-emergent neuropathy

T2 - Prevalence, risk factors and outcome in 100 patients with myelofibrosis

AU - Abdelrahman, Ramy A.

AU - Begna, Kebede H.

AU - Al-Kali, Aref

AU - Hogan, William J.s.

AU - Litzow, Mark R.

AU - Pardanani, Animesh

AU - Tefferi, Ayalew

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment-emergent peripheral neuropathy (TE-PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE-PN onset was 32 weeks and duration 11 months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE-PN was significantly associated with treatment response (P = 0·02) and longer survival (P = 0·048) but significance was lost during multivariate analysis that included treatment duration. TE-PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide.

AB - Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment-emergent peripheral neuropathy (TE-PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE-PN onset was 32 weeks and duration 11 months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE-PN was significantly associated with treatment response (P = 0·02) and longer survival (P = 0·048) but significance was lost during multivariate analysis that included treatment duration. TE-PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide.

KW - Momelotinib

KW - Myelofibrosis

KW - Myeloproliferative

KW - Neuropathy

UR - http://www.scopus.com/inward/record.url?scp=84924965031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924965031&partnerID=8YFLogxK

U2 - 10.1111/bjh.13262

DO - 10.1111/bjh.13262

M3 - Article

C2 - 25511866

AN - SCOPUS:84924965031

SN - 0007-1048

VL - 169

SP - 77

EP - 80

JO - British journal of haematology

JF - British journal of haematology

IS - 1

ER -

Momelotinib treatment-emergent neuropathy: Prevalence, risk factors and outcome in 100 patients with myelofibrosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this